Lv31
294 积分 2024-10-07 加入
Clinical and genomic characterization of Chinese patients with functional high-risk multiple myeloma: A real-world validation study
4分钟前
求助中
European Myeloma Network Consensus Statement on Functional High‐Risk Multiple Myeloma
10天前
已完结
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial
15天前
已关闭
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial
20天前
已完结
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
1个月前
已完结
High‐risk multiple myeloma: Redefining genetic, clinical, and functional high‐risk disease in the era of molecular medicine and immunotherapy
1个月前
已完结
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study
1个月前
已完结
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
1个月前
已完结
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
1个月前
已完结
European Myeloma Network Group Review and Consensus Statement on Primary Plasma Cell Leukemia
1个月前
已完结
皖公网安备34019202002308
